<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333329</url>
  </required_header>
  <id_info>
    <org_study_id>STU_14_032</org_study_id>
    <nct_id>NCT04333329</nct_id>
  </id_info>
  <brief_title>Transcranial Pulse Stimulation (TPS) for Alzheimer's Disease (AD)</brief_title>
  <official_title>Transcranial Pulse Stimulation for Alzheimer's Disease in an Open Prospective Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Storz Medical AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rheintalklinik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Storz Medical AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective open comprehensive proof-of-principle pilot study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective open comprehensive proof-of-principle pilot study with patients of mild
      to moderate Alzheimer's Disease who have been treated with transcranial pulse stimulation
      (TPS)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2015</start_date>
  <completion_date type="Actual">February 15, 2017</completion_date>
  <primary_completion_date type="Actual">February 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Consortium to Establish a Registry for Alzheimer's Disease (CERAD) - Total Score</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>CERAD is a cognitive test battery which is normalized for age, gender and education. The CERAD total score ranges from 0 to 100 with 100 meaning &quot;normal cognitive ability&quot; and 0 meaning &quot;severe cognitive impairment&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Device Effects</measure>
    <time_frame>within 3 months follow-up</time_frame>
    <description>Number of ADEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consortium to Establish a Registry for Alzheimer's Disease (CERAD) - Total Score</measure>
    <time_frame>Immediately post treatment (at 2 weeks)</time_frame>
    <description>CERAD is a cognitive test battery which is normalized for age, gender and education. The CERAD total score ranges from 0 to 100 with 100 meaning &quot;normal cognitive ability&quot; and 0 meaning &quot;severe cognitive impairment&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consortium to Establish a Registry for Alzheimer's Disease (CERAD) - Total Score</measure>
    <time_frame>1 month after treatment (at 6 weeks)</time_frame>
    <description>CERAD is a cognitive test battery which is normalized for age, gender and education. The CERAD total score ranges from 0 to 100 with 100 meaning &quot;normal cognitive ability&quot; and 0 meaning &quot;severe cognitive impairment&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental-State Examination (MMSE)</measure>
    <time_frame>Immediately post treatment (at 2 weeks)</time_frame>
    <description>The MMSE consists of 10 items that cover orientation, short term memory, attentional capabilities, arithmetic performance and language functions. Scoring is possible between 0 (worst) and 30 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental-State Examination (MMSE)</measure>
    <time_frame>1 month after treatment (at 6 weeks)</time_frame>
    <description>The MMSE consists of 10 items that cover orientation, short term memory, attentional capabilities, arithmetic performance and language functions. Scoring is possible between 0 (worst) and 30 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental-State Examination (MMSE)</measure>
    <time_frame>3 months after treatment (at 14 weeks)</time_frame>
    <description>The MMSE consists of 10 items that cover orientation, short term memory, attentional capabilities, arithmetic performance and language functions. Scoring is possible between 0 (worst) and 30 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clock Drawing Test (CDT)</measure>
    <time_frame>Immediately post treatment (at 2 weeks)</time_frame>
    <description>The clock drawing test is used to assess visuoconstruction abilities. The subject is asked to draw the face of a clock with all numbers and to set the hands for a specified time (hh:mm). Scores range from 0 (worst) to 7 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clock Drawing Test (CDT)</measure>
    <time_frame>1 month after treatment (at 6 weeks)</time_frame>
    <description>The clock drawing test is used to assess visuoconstruction abilities. The subject is asked to draw the face of a clock with all numbers and to set the hands for a specified time (hh:mm). Scores range from 0 (worst) to 7 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clock Drawing Test (CDT)</measure>
    <time_frame>3 months after treatment (at 14 weeks)</time_frame>
    <description>The clock drawing test is used to assess visuoconstruction abilities. The subject is asked to draw the face of a clock with all numbers and to set the hands for a specified time (hh:mm). Scores range from 0 (worst) to 7 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>Immediately post treatment (at 2 weeks)</time_frame>
    <description>The BDI measures the severity of depression. It is a 21-item questionnaire for self-evaluation with 0-3 scores per item. The total score is the sum of all items. It ranges from 0 (normal state) to 63 (severe depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>1 month after treatment (at 6 weeks)</time_frame>
    <description>The BDI measures the severity of depression. It is a 21-item questionnaire for self-evaluation with 0-3 scores per item. The total score is the sum of all items. It ranges from 0 (normal state) to 63 (severe depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>3 months after treatment (at 14 weeks)</time_frame>
    <description>The BDI measures the severity of depression. It is a 21-item questionnaire for self-evaluation with 0-3 scores per item. The total score is the sum of all items. It ranges from 0 (normal state) to 63 (severe depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale - short form (GDS-15)</measure>
    <time_frame>Immediately post treatment (at 2 weeks)</time_frame>
    <description>The Geriatric Depression Scale (GDS) is a questionnaire to assess depression in the elderly population. This scale generates self-evaluation scores concerning various aspects with relevance for the depressive disease (e.g. mood, drive, anxiety). The short form contains 15 items. The GDS-15 score ranges from 0 (normal state) to 15 (severe depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale - short form (GDS-15)</measure>
    <time_frame>1 month after treatment (at 6 weeks)</time_frame>
    <description>The Geriatric Depression Scale (GDS) is a questionnaire to assess depression in the elderly population. This scale generates self-evaluation scores concerning various aspects with relevance for the depressive disease (e.g. mood, drive, anxiety). The short form contains 15 items. The GDS-15 score ranges from 0 (normal state) to 15 (severe depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale - short form (GDS-15)</measure>
    <time_frame>3 months after treatment (at 14 weeks)</time_frame>
    <description>The Geriatric Depression Scale (GDS) is a questionnaire to assess depression in the elderly population. This scale generates self-evaluation scores concerning various aspects with relevance for the depressive disease (e.g. mood, drive, anxiety). The short form contains 15 items. The GDS-15 score ranges from 0 (normal state) to 15 (severe depression).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>AD Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients were treated with the TPS device (new name: NEUROLITH (Storz Medical AG))
- 6 sessions within 2 weeks, each sessions consisting of 6000 TPS pulses of 0.2 mJ/mmÂ²</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NEUROLITH</intervention_name>
    <description>transcranial pulse stimulation (TPS)</description>
    <arm_group_label>AD Patients</arm_group_label>
    <other_name>transcranial pulse stimulation (TPS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically stable patients with probable Alzheimer's Disease (Diagnosis according to
             ICDâ10 Criteria (F00))

          -  MMSE â¥ 10: Mild and moderate Alzheimer's Disease according to AWMF Register, S3
             Guidelines of DGN 038/013 and DEGAM 035/021

          -  At least 3 months of stable antidementia therapy or no antidementia therapy necessary
             (Patients need to continue their standard treatment within the clinical investigation
             according to the guidelines as TPS is considered an additional treatment to standard
             therapy)

          -  Signed written informed consent

          -  18 years â¤ Age â¤ 85 years

          -  Monthly pregnancy tests for female patients in childbearing age

        Exclusion Criteria:

          -  Nonâcompliance with the protocol (including CERADâplus)

          -  Pregnancy

          -  Breastâfeeding women

          -  Microbubbles (contrast agents) in application area

          -  Cerebral pathology unrelated to Alzheimer's disease

          -  Metallic objects in the head

          -  Neurosurgical intervention of the brain / Craniotomy

          -  Cardiac disorders

          -  History of psychiatric diseases before development of dementia

          -  Hemophilia or other blood clotting disorders

          -  Cortisone treatment up to 6 months before first treatment

          -  Other conditions implying increased risk according to the judgement of the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Lohse-Busch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheintalklinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheintalklinik</name>
      <address>
        <city>Bad Krozingen</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

